A subscription to JoVE is required to view this content. Sign in or start your free trial.
Influenza neutralizing antibodies correlate with protection of influenza infections. Microneutralization assays measure neutralizing antibodies in human sera and are often used for influenza human serology. We describe a microneutralization assay using MDCK-SIAT1 cells to measure neutralizing antibody titers to contemporary 3C.2a and 3C.3a A(H3N2) viruses following influenza vaccination or infection.
Neutralizing antibodies against hemagglutinin (HA) of influenza viruses are considered the main immune mechanism that correlates with protection for influenza infections. Microneutralization (MN) assays are often used to measure neutralizing antibody responses in human sera after influenza vaccination or infection. Madine Darby Canine Kidney (MDCK) cells are the commonly used cell substrate for MN assays. However, currently circulating 3C.2a and 3C.3a A(H3N2) influenza viruses have acquired altered receptor binding specificity. The MDCK-SIAT1 cell line with increased α-2,6 sialic galactose moieties on the surface has proven to provide improved infectivity and more faithful replications than conventional MDCK cells for these contemporary A(H3N2) viruses. Here, we describe a MN assay using MDCK-SIAT1 cells that has been optimized to quantify neutralizing antibody titers to these contemporary A(H3N2) viruses. In this protocol, heat inactivated sera containing neutralizing antibodies are first serially diluted, then incubated with 100 TCID50/well of influenza A(H3N2) viruses to allow antibodies in the sera to bind to the viruses. MDCK-SIAT1 cells are then added to the virus-antibody mixture, and incubated for 18 - 20 h at 37 °C, 5% CO2 to allow A(H3N2) viruses to infect MDCK-SIAT1 cells. After overnight incubation, plates are fixed and the amount of virus in each well is quantified by an enzyme-linked immunosorbent assay (ELISA) using anti-influenza A nucleoprotein (NP) monoclonal antibodies. Neutralizing antibody titer is defined as the reciprocal of the highest serum dilution that provides ≥50% inhibition of virus infectivity.
Influenza viruses continue to cause morbidity and mortality in the human population each year. HA is the major surface glycoprotein of influenza viruses. Neutralizing antibodies targeting HA are the main immune mechanism that correlates with protection of influenza infection1,2. Hemagglutination inhibition (HI) assays and MN assays are two methods widely used to measure antibody responses in human sera after influenza infection or vaccination3. The HI assay measures antibody inhibition of virus hemagglutination of red blood cells and is considered a surrogate assay. Unlike HI, the MN as....
All influenza viruses should be handled according to appropriate biosafety level requirements (BSL-2 or higher) as defined in the Biosafety on Microbiological and Biomedical Laboratories (BMBL)12.
1. Preparation of Reagents and Starting Material
Determination of the infectivity of the virus stocks is the first step in the MN assay. Figure 2 illustrates the plate layout to determine the TCID50 of the virus stocks. For virus stocks with unknown infectivity, the virus can be titrated from multiple pre-dilutions, for example both 10-2 and 10-3, in order to capture the best titration curve to calculate infectivity of the virus. The virus amount used in the MN assay should .......
The MN assay is one of the main assays used for influenza serology to detect antibody responses following influenza infection or vaccination. Titers generated from MN assays are often used as the primary outcome of many influenza seroepidemiology studies. MN assays are also widely used for sero-diagnosis, and the evaluation of vaccine immunogenicity. International inter-lab studies have been conducted to compare MN assays performed in multiple laboratories14.
In contras.......
We thank Dr. Xiuhua Lu, Dr. Feng Liu, and Ms. Ashley Burroughs from the Influenza Division of the CDC for their critical review and assistance in preparation of this manuscript. We thank Dr. Adrian Reber from Influenza Division of the CDC for his assistance in preparing the graphics of Figure 3. Lastly, we thank Dr. M. Matrosovich, Marburg, Germany for providing the MDCK-SIAT1 cells.
....Name | Company | Catalog Number | Comments |
Dulbecco’s Modified Eagle Medium (DMEM) with high Glucose | Life Science | 11965 | A critical component of Sterile Cell Culture, Virus Propagation and Virus Diluent Media |
Fetal bovine serum (FBS) | Hyclone | SH30070.03 | |
Bovine Serum Albumin (BSA) Fraction V, Protase Free | Sigma-Aldrich | 3117332001 | |
L-Glutamine | Life Science | 25030-081 | |
Sodium pyruvate | Life Science | 11360-070 | |
Geneticin G-418 disulfate salt | Sigma-Aldrich | A1720-5G | |
HEPES | Life Science | 15630-080 | |
Penicillin/Streptomycin | Life Science | 15140-122 | |
Acetone | VWR | 67-64-1 | Used at an 80% concentration |
Phosphate-Citrate Buffer with Sodium Perborate | Sigma-Aldrich | SLBF2806V | |
O-Phenylenediamine Dihydrochloride tablet | Sigma-Aldrich | SLBQ1086V | 1 tablet per 100ml of cell culture grade water |
Sulfuric Acid | Fisher Scientific | A510-P500 | Used 0.5M final concentration |
Ethanol, Denatured, 4L | VWR | EM-AX0422-3 | Used at an 70% concentration |
Trypsin-EDTA | Life Science | 1748048 | |
RDE II "Seiken" | Denka Seiken | 370013 | |
Tween 20 | Sigma-Aldrich | P1379-500ml | |
Anti-NP mouse monoclonal Ab | Millipore pool | MAB 8257 MAB 8258 | |
Anti-mouse IgG HRP | KPL | 074-1802 | |
96-well flat-bottom plates | Thermo Scientific | 3455 | |
Plate reader | Molecular Device | Spectromax 384 plus | |
Cell Culture Flask 162 cm2/Vent Cap | Corning/VWR | 3151 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2025 MyJoVE Corporation. All rights reserved